Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Davids on Results of Obinutuzumab With Ibrutinib in CLL

Matthew S. Davids, MD, MMSc
Published: Wednesday, Jan 24, 2018



Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia (CLL), discusses the initial results of a phase Ib study of ibrutinib (Imbruvica) in combination with obinutuzumab (Gazyva) in patients with relapsed or refractory CLL.

The first 28 patients of this trial were randomized to 3 arms. The results have been interesting in terms of the difference in infusion reactions, explains Davids. In the first arm with single-agent obinutuzumab, there was a 63% rate of infusion reactions. In arm B, there were no infusion reactions, and in arm C there was 1 reaction, which was dramatically less than expected.

Even though the trial is not completely accrued, there is a clear signal to start ibrutinib before or at the same time as obinutuzumab.

In terms of efficacy, the results also seem promising across the different arms. There is a high rate of radiographic complete remission. Davids says that this will be an effective combination and inform the design of future combination studies, and physicians will be able to sequence ibrutinib and obinutuzumab in the optimal way for patient safety and efficacy.
 


Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia (CLL), discusses the initial results of a phase Ib study of ibrutinib (Imbruvica) in combination with obinutuzumab (Gazyva) in patients with relapsed or refractory CLL.

The first 28 patients of this trial were randomized to 3 arms. The results have been interesting in terms of the difference in infusion reactions, explains Davids. In the first arm with single-agent obinutuzumab, there was a 63% rate of infusion reactions. In arm B, there were no infusion reactions, and in arm C there was 1 reaction, which was dramatically less than expected.

Even though the trial is not completely accrued, there is a clear signal to start ibrutinib before or at the same time as obinutuzumab.

In terms of efficacy, the results also seem promising across the different arms. There is a high rate of radiographic complete remission. Davids says that this will be an effective combination and inform the design of future combination studies, and physicians will be able to sequence ibrutinib and obinutuzumab in the optimal way for patient safety and efficacy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x